Actinium Pharmaceuticals (ATNM) Competitors $1.21 -0.04 (-3.20%) Closing price 04:00 PM EasternExtended Trading$1.21 0.00 (0.00%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock ATNM vs. CGC, NGNE, DBVT, IPHA, FULC, NBTX, ACTU, MOLN, RZLT, and ACIUShould you be buying Actinium Pharmaceuticals stock or one of its competitors? The main competitors of Actinium Pharmaceuticals include Canopy Growth (CGC), Neurogene (NGNE), DBV Technologies (DBVT), Innate Pharma (IPHA), Fulcrum Therapeutics (FULC), Nanobiotix (NBTX), Actuate Therapeutics (ACTU), Molecular Partners (MOLN), Rezolute (RZLT), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry. Actinium Pharmaceuticals vs. Canopy Growth Neurogene DBV Technologies Innate Pharma Fulcrum Therapeutics Nanobiotix Actuate Therapeutics Molecular Partners Rezolute AC Immune Actinium Pharmaceuticals (NYSE:ATNM) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation. Do analysts rate ATNM or CGC? Actinium Pharmaceuticals currently has a consensus price target of $7.40, suggesting a potential upside of 492.00%. Canopy Growth has a consensus price target of $2.00, suggesting a potential upside of 69.49%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Canopy Growth.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Canopy Growth 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is ATNM or CGC more profitable? Actinium Pharmaceuticals has a net margin of 0.00% compared to Canopy Growth's net margin of -156.98%. Canopy Growth's return on equity of -56.52% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actinium PharmaceuticalsN/A -100.85% -47.89% Canopy Growth -156.98%-56.52%-24.18% Do insiders and institutionals believe in ATNM or CGC? 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 3.3% of Canopy Growth shares are held by institutional investors. 6.0% of Actinium Pharmaceuticals shares are held by company insiders. Comparatively, 1.3% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better valuation & earnings, ATNM or CGC? Actinium Pharmaceuticals has higher earnings, but lower revenue than Canopy Growth. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActinium Pharmaceuticals$81K481.42-$48.82M-$1.39-0.90Canopy Growth$276.75M0.68-$487.23M-$3.80-0.31 Does the media prefer ATNM or CGC? In the previous week, Canopy Growth had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 15 mentions for Canopy Growth and 14 mentions for Actinium Pharmaceuticals. Canopy Growth's average media sentiment score of 0.13 beat Actinium Pharmaceuticals' score of 0.01 indicating that Canopy Growth is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Canopy Growth 0 Very Positive mention(s) 1 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, ATNM or CGC? Actinium Pharmaceuticals has a beta of -0.27, meaning that its stock price is 127% less volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Does the MarketBeat Community favor ATNM or CGC? Canopy Growth received 11 more outperform votes than Actinium Pharmaceuticals when rated by MarketBeat users. However, 47.37% of users gave Actinium Pharmaceuticals an outperform vote while only 19.23% of users gave Canopy Growth an outperform vote. CompanyUnderperformOutperformActinium PharmaceuticalsOutperform Votes947.37% Underperform Votes1052.63% Canopy GrowthOutperform Votes2019.23%Underperform Votes8480.77% SummaryActinium Pharmaceuticals beats Canopy Growth on 10 of the 18 factors compared between the two stocks. Remove Ads Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNM vs. The Competition Export to ExcelMetricActinium PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$39.00M$6.27B$5.29B$18.32BDividend YieldN/A3.24%5.11%4.23%P/E Ratio-0.906.6921.6930.99Price / Sales481.42222.71373.9626.11Price / CashN/A65.6738.1517.53Price / Book0.955.776.364.26Net Income-$48.82M$142.01M$3.20B$1.02B7 Day Performance8.70%5.79%3.96%2.03%1 Month Performance-3.85%-15.47%-10.34%-8.51%1 Year PerformanceN/A-10.99%10.38%1.68% Actinium Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNMActinium Pharmaceuticals2.0126 of 5 stars$1.21-3.2%$7.40+511.6%N/A$37.75M$81,000.00-0.8730CGCCanopy Growth2.2301 of 5 stars$1.03+9.6%$2.00+94.2%-82.4%$163.37M$276.75M-0.273,150Options VolumeNews CoverageNGNENeurogene2.1271 of 5 stars$10.89-1.0%$47.20+333.4%-69.4%$162.59M$925,000.00-2.5590Analyst ForecastGap DownDBVTDBV Technologies2.7978 of 5 stars$7.79+6.4%$22.50+188.8%+12.9%$160.23M$15.73M-1.7380Earnings ReportAnalyst ForecastShort Interest ↑IPHAInnate Pharma2.4886 of 5 stars$1.90+1.3%$11.50+505.3%-25.1%$159.28M$12.63M0.00220News CoveragePositive NewsGap UpFULCFulcrum Therapeutics2.1716 of 5 stars$2.92+8.6%$8.63+195.4%-58.7%$157.62M$80M-9.42100Short Interest ↓Gap UpNBTXNanobiotix2.2923 of 5 stars$3.33flat$8.00+140.2%-40.6%$156.95M$-11,609,000.000.00100ACTUActuate TherapeuticsN/A$8.00+4.4%$20.00+150.0%N/A$156.26MN/A0.0010News CoverageMOLNMolecular Partners2.0864 of 5 stars$3.86-0.3%$12.00+210.9%-8.7%$155.85M$4.97M-1.80180Gap UpRZLTRezolute2.8711 of 5 stars$2.57+4.0%$24.38+848.4%-22.4%$155.58MN/A-2.1140Positive NewsGap UpACIUAC Immune2.5211 of 5 stars$1.52-2.6%$12.00+689.5%-38.8%$152.62M$27.31M-3.30140Analyst RevisionNews CoveragePositive News Remove Ads Related Companies and Tools Related Companies Canopy Growth Alternatives Neurogene Alternatives DBV Technologies Alternatives Innate Pharma Alternatives Fulcrum Therapeutics Alternatives Nanobiotix Alternatives Actuate Therapeutics Alternatives Molecular Partners Alternatives Rezolute Alternatives AC Immune Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ATNM) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATNM Stock Free ATNM Stock Alerts